Scout Clinical and ICON Findings From Rare Disease Trial Participant Focus Group
Scout Clinical, a provider of comprehensive clinical trial patient services, has announced the results of their rare disease clinical trial patient focus group. Conducted in partnership with ICON plc, the initiative sought to amplify the voices of those whose lives are touched by rare diseases.
The information from these focus groups addresses the gap between the experiences and perceptions of patients and the participation support services provided to them during clinical trials. The series found:
- Rare disease trial participation exposes participants to significant pressures across a variety of categories—including financial, physical, logistical, psychological and emotional—all incremental to the burdens participants already bear by virtue of living with a rare disease.
- Trial participation support services had effectively helped respondents overcome barriers to participation.
- Fully 30% of participants identified emotional support/counseling as a service that could make it easier for them to participate in a clinical trial.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
